LENZ Therapeutics, Inc. LENZ

The analyst fair value estimate for LENZ Therapeutics has shifted from US$32.00 to about US$26.83 per share, which now lines up more closely with the US$7 price target cluster that many firms reference. This reset reflects the more cautious stance in recent research, where several analysts cut price targets and moved to Neutral while they reassess the VIZZ launch and the company’s cash support. As you read on, you will see how these moving targets shape the evolving LENZ Therapeutics...

Strong cash position and expanding global partnerships offset modest Q2 product revenue growth as the company scales commercial execution.

Moby summary of LENZ Therapeutics, Inc.'s Q2 2026 earnings call

Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy channel purchasing multiple monthly packs since launch, tracking to five packs annually VIZZ prescription growth accelerated with launch of telehealth channel in July 2026 Management to host conference call today, August 11, 2026, at 4:30 p.m. EDT SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LE

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights. T

The fair value estimate for LENZ Therapeutics has been revised from US$53.71 to US$32.00, signaling a reset in where analysts currently see the stock’s potential. Recent commentary shows a more mixed stance, with some analysts still highlighting long term upside while others point to execution risks and valuation resets behind these target cuts, including references to US$20, US$8 and US$10 levels. As you read on, you will see how these shifting price targets fit into the broader LENZ...

VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals Telehealth offers patients the convenience of an integrated online evaluation by independent licensed eye care providers, e-pharmacy prescription fulfillment and home delivery Launch of telehealth alongside a nationwide TV advertising campaign featuring brand spokesperson Sarah Jessica Parker is expected to expand consumer awareness, access, and adopt

Exclusive license and commercialization agreement includes a significant profit share of gross margin from product sales in addition to an upfront license payment to LENZSAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”) today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize VIZZ™ for the treatment of presbyopia in Australia and New Ze

LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and commercialize VIZZ, also known as LNZ100, in Greater China. Under the agreement, Everest Medicines (HKEX:1952) takes on development and commercialization of the drug in the Greater China...

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced that Everest Medicines (HKEX1952, or “Everest”), has entered into an Asset Purc